CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma

envie a um amigo share this

CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma

Sexta, 26.01.2018


Ricardo Celestino1,2,3,4, Torfinn Nome3,5, Ana Pestana1,2,6, Andreas M. Hoff3,5, A. Pedro Gonçalves1,6,7, Luísa Pereira1,2, Bruno Cavadas1,2, Catarina Eloy1,2, Trine Bjøro8,9, Manuel Sobrinho-Simões1,2,10,11, Rolf I. Skotheim3,5, Paula Soares1,2,10

1- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal;

2- IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135 Porto, Portugal;

3- Department of Molecular Oncology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway; 4- School of Allied Health Technologies, Polytechnic of Porto, 4400-330 Vila Nova de Gaia, Portugal;

5- Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0424 Oslo, Norway;

6- ICBAS - Abel Salazar Biomedical Sciences Institute of the University of Porto, 4050-313 Porto, Portugal;

7- IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, 4200-135 Porto, Portugal;

8- Department of Medical Biochemistry, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway;

9- Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway;

10- Medical Faculty, University of Porto, 4200-319 Porto, Portugal;

11- Department of Pathology, Centro Hospitalar de São João, 4200-319 Porto, Portugal.


CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. Background: The prognostic variability of thyroid carcinomas has led to the search for accurate biomarkers at the molecular level. Follicular thyroid carcinoma (FTC) is a typical example of differentiated thyroid carcinomas (DTC) in which challenges are faced in the differential diagnosis. Methods: We used high-throughput paired-end RNA sequencing technology to study four cases of FTC with different degree of capsular invasion: two minimally invasive (mFTC) and two widely invasive FTC (wFTC). We searched by genes differentially expressed between mFTC and wFTC, in an attempt to find biomarkers of thyroid cancer diagnosis and/or progression. Selected biomarkers were validated by real-time quantitative PCR in 137 frozen thyroid samples and in an independent dataset (TCGA), evaluating the diagnostic and the prognostic performance of the candidate biomarkers. Results: We identified 17 genes significantly differentially expressed between mFTC and wFTC. C1QL1, LCN2, CRABP1 and CILP were differentially expressed in DTC in comparison with normal thyroid tissues. LCN2 and CRABP1 were also differentially expressed in DTC when compared with follicular thyroid adenoma. Additionally, overexpression of LCN2 and C1QL1 were found to be independent predictors of extrathyroidal extension in DTC. Conclusions: We conclude that the underexpression of CRABP1 and the overexpression of LCN2 may be useful diagnostic biomarkers in thyroid tumours with questionable malignity, and the overexpression of LCN2 and C1QL1 may be useful for prognostic purposes.


BMC Cancer

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3948-3